Active, not recruitingPhase 3NCT04628494
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Intervention
- Epcoritamab(biological)
- Enrollment
- 484 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
- Community Health Network Cancer Center North, Indianapolis, Indiana, United States
- University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
- Henry Ford Health System, Jackson, Michigan, United States
- MMCORC Attn Delaney Anderson, Saint Louis Park, Minnesota, United States
- MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States
- Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
- The Christ Hospital Cancer Center, Cincinnati, Ohio, United States
- TriHealth Cancer Institute- Good Samaritan Hospital, Cincinnati, Ohio, United States
- Brooke Army Medical Center, Fort Sam Houston, Texas, United States
- Community Cancer Trials of Utah, Ogden, Utah, United States
- LDS Hospital, Salt Lake City, Utah, United States
- Virginia Commonwealth University (VCU) Massey Cancer Center, Richmond, Virginia, United States
- North Star Lodge Cancer Center, Yakima, Washington, United States
- Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04628494 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGPHASE2NCT05934448Pembro Plus CAR T-cell Therapy in R/R in PMBCLJennifer Crombie, MD
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →